Transcatheter Aortic Valve Replacement in Low Risk Patients

March 01, 2016
BH16-235
Heart
Dr. Ashequl Islam
Baystate Medical Center
759 Chestnut Street
Springfield, MA 01199
The purpose of this study is to demonstrate that the safety and effectiveness of the Medtronic Transcatheter Aortic Valve Replacement (TAVR) system as measured by rates of all-cause mortality or disabling stroke at two years is non-inferior to Surgical Aortic Valve Replacement (SAVR) in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR.

• At low risk for SAVR
• Severe aortic stenosis

Patients will be seen at pre and post-procedure, discharge, 30 days, and, 1 year.
Recruiting
Annette Scarnici, RN
413-794-9076